Oxford-Harrington Rare Disease Centre operates a transatlantic model that embeds industry expertise directly into academic rare disease programs. The partnership between University of Oxford and Harrington Discovery Institute has committed $250 million to address a market where 95% of 7,000
In the pharmaceutical industry, where relationships are typically long-term and the costs of switching suppliers are often prohibitive, a robust and collaborative planning phase for supplier selection is critical. Poor supplier selection decisions can cascade into compromised product quality, supply
The pharmaceutical contract development and manufacturing organization (CDMO) sector is experiencing unprecedented growth, driven by increasing demand for specialized expertise in clinical trial compliance and regulatory adherence. As drug development becomes more complex and globalized, pharmaceutical companies are increasingly turning
The pharmaceutical supply chain has evolved into a complex global network where maintaining product quality from factory to patient requires rigorous oversight at every touchpoint. Good Distribution Practice (GDP) represents the quality framework that ensures medicines retain their safety, efficacy,
The pharmaceutical cold chain management sector represents one of the fastest-growing segments in contract development and manufacturing organization (CDMO) services, driven by the explosive growth of temperature-sensitive biologics, vaccines, and advanced therapies. As biopharmaceutical innovation accelerates toward complex modalities requiring
Pennsylvania biotech Ocugen advances a modifier gene therapy approach that resets retinal cellular networks rather than replacing individual mutations, positioning OCU400 to address up to 300,000 RP patients in the U.S. and Europe—far beyond the 1-2% eligible for current mutation-specific
Founded just three months ago in August 2025, London-based Kindling Bio is inverting the standard adult-to-child drug translation model by developing a gene therapy platform designed specifically for childhood solid tumors from the outset. With £250k in launch funding and
The global peptide therapeutics market stands at a pivotal moment in pharmaceutical development. After years of being considered challenging to manufacture and unstable for therapeutic use, peptides have emerged as one of the fastest-growing segments in the pharmaceutical industry. Peptide
Norwegian Biotech Secures FDA IND Clearance for Novel Mechanism in Brain Cancer Norwegian biotech Hemispherian brings a distinctive approach to glioblastoma treatment with GLIX1, a first-in-class small-molecule TET2 agonist that recently cleared an IND with the U.S. FDA. CEO Zeno
AstraZeneca has become the second major pharmaceutical manufacturer to sign a “most favored nation” pricing agreement with the Trump administration, committing to match the lowest drug prices offered in developed nations for Medicaid programs and newly launched products. President Donald
